Mr. Paul Duffy reports

AIML APPOINTS DR. PAUL DORIAN AS MEDICAL INNOVATION ARCHITECT AND HEAD OF THE MEDICAL ADVISORY BOARD

AI-ML Innovations Inc. has appointed Dr. Paul Dorian, MD, MSc, as the company's medical innovation architect (MIA) and head of the company's medical advisory board, effective immediately.

Dr. Dorian succeeds Peter kendall, who previously served as chair of the medical advisory board. This leadership transition comes as AI-ML enters a phase of advanced clinical validation, regulatory engagement and global deployment of its AI-powered (artificial intelligence) cardiac diagnostic technologies.

Dr. Dorian has been working closely with AI-ML for several months, contributing to product strategy, clinical positioning and innovation initiatives across the company's MaxYield, CardioYield and Insight360 platforms. His formal appointment further strengthens the clinical leadership underpinning AI-ML's next phase of growth.

Dr. Dorian commented: "I have been impressed by the rigour of AI-ML's science and the ambition of its vision. The company is addressing real, unmet needs in cardiac diagnostics by combining advanced AI with practical, scalable clinical solutions. I look forward to helping guide innovation, clinical strategy and the translation of AI-ML's technology into clinically meaningful impact."

"Dr. Dorian's appointment marks a pivotal milestone for AI-ML," said Paul Duffy, executive chairman and chief executive officer of AI-ML. "He brings unparalleled expertise in cardiac electrophysiology, clinical research and health-system innovation. As we expand into regulated clinical markets and large-scale deployments, his leadership will help ensure our technology meets the highest standards of clinical relevance, safety and impact."

Esmat Naikyar, president of Neural Cloud Solutions Inc. and chief product officer of AI-ML, added: "Dr. Dorian's insights have already influenced our product direction in meaningful ways. His deep understanding of arrhythmia care, ambulatory monitoring and patient-reported outcomes strengthens our ability to build tools that are not only technologically advanced but clinically valuable."

AI-ML established its medical advisory board in May, 2025, to guide clinical studies, regulatory strategy and real-world deployment of its AI-driven ECG (electrocardiogram) signal-processing platforms. Dr. Dorian's appointment as head reinforces the company's commitment to aligning cutting-edge AI innovation with front-line clinical expertise.

About Dr. Dorian

Dr. Dorian is a professor of medicine (cardiology and clinical pharmacology) at the University of Toronto, a staff cardiac electrophysiologist at St. Michael's Hospital and a staff scientist at the Li Ka Shing Knowledge Institute.

He received his medical degree from McGill University and completed postgraduate training in internal medicine, clinical pharmacology and cardiology at the University of Toronto, followed by a fellowship in cardiac electrophysiology at Stanford University.

Dr. Dorian previously served as director of the division of cardiology at the University of Toronto (2009 to 2019) and president of the Canadian Heart Rhythm Society (2013 to 2014). He is a recipient of the University of Toronto Department of Medicine Research Award as well as the Canadian Cardiovascular Society and Canadian Heart Rhythm Society Achievement Awards.

He founded the cardiac electrophysiology program at St. Michael's Hospital in 1990 and has led landmark research in:

• Ambulatory cardiac monitoring and wearable diagnostics;
• Sudden cardiac death prevention;
• Atrial fibrillation systems of care and patient-reported outcomes.

Dr. Dorian designed and led the development of widely adopted quality-of-life assessment tools in atrial fibrillation, including the CCS-SAF, AFSS and AFEQT scales. He has served on multiple national guideline committees and steering committees for international multicentre clinical trials.

He has written over 580 peer-reviewed publications and is an associate editor of Electrophysiological Disorders of the Heart.

About AI-ML Innovations Inc.

AI-ML Innovations is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. The company's proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights -- supporting earlier diagnosis, personalized treatment and more effective care.

AI-ML's shares trade on the Canadian Securities Exchange (symbol: AIML), the OTCQB Venture Market (symbol: AIMLF) and the Frankfurt Stock Exchange (symbol: 42FB).

We seek Safe Harbor.